FDA Grants Fast Track Status to Climb Bio’s Budoprutug for Rare Kidney Disease — Climb Bio, Inc.

Event summary

FDA grants Fast Track Designation to Climb Bio’s budoprutug for primary membranous nephropathy (pMN), a rare kidney disease with no approved treatments.
Phase 1b study showed complete B-cell depletion in all patients, serologic remission in evaluable patients, and favorable safety profile.
Phase 2 global open-label study (PrisMN) ongoing; initial data expected in H2 2026.
Budoprutug also being evaluated for immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

The big picture

Climb Bio’s Fast Track Designation for budoprutug underscores the urgent need for therapies in primary membranous nephropathy, a rare and debilitating kidney disease. The designation accelerates development efforts and highlights the potential of anti-CD19 monoclonal antibodies in treating immune-mediated diseases. With no FDA-approved treatments currently available, successful clinical outcomes could position Climb Bio as a key player in this underserved market.

What we're watching

Clinical Progress: How the Phase 2 study results will impact budoprutug’s path to Phase 3 and potential approval.
Regulatory Strategy: Whether Fast Track Designation accelerates interactions with FDA and expedites development timelines.
Market Positioning: The pace at which Climb Bio can establish budoprutug as a leading therapy in the pMN space.